6 results about "Diabetic rat" patented technology

The present application relates to a kind of porous scaffold for repairing bone defect loaded with black phosphorus active oxygen elimination and slow-release drug and its preparation method;The scaffold includes the amino cation polymer grafted with the phenylboronic acid (PBA) and cyclodextrin (CD) that can eliminate active oxygen, black phosphorus nanosheet (BP) and scaffold material poly (lactic acid-glycolic acid) (PLGA).The porous scaffold loads a large number of black phosphorus nanosheet that can be hydrolyzed into bone repair nutrients, and the porous structure provides sufficient space for cell migration and growth, realizes the good repair of bone.Active oxygen elimination ability, can eliminate active oxygen in diabetic microenvironment.In addition, cyclodextrin can load a variety of drugs, such as osteogenic differentiation induction drug, and realize the slow release of drug.The porous scaffold has good biocompatibility, and the degradation product is harmless to human body, can be used for the tissue repair of bone defect, can be widely applied in the field of biological medicine and tissue engineering, and has been proved to have good repair ability in the diabetic rat skull defect model.

The invention discloses eye drops for treating vascular hyperplasia of eyes and a preparation method of the eye drops, and belongs to the technical field of biological pharmacy. The eye drops comprise a recombinant human angiostatin protein, an endostatin protein and a pharmaceutically acceptable carrier, wherein the recombinant human angiostatin protein and the endostatin protein are used for preparing the eye drops. Experiments show that the eye drops show remarkable vascular inhibition activity in a chick embryo chorioallantoic membrane model and a diabetic rat retina hyperplasia model, and the two proteins are combined for use to achieve a synergistic effect; the invention provides a safe and effective new way for local treatment of ocular vascular hyperplasia diseases.

The application belongs to the field of biomedical materials, and discloses a multifunctional hydrogel suitable for diabetic wound healing. The hydrogel is compounded by HA-Tris, EPL-Cpb and MXene / Mn composite nanoparticles in a mass ratio of 2:1:(0-0.2), and is rapidly crosslinked in 1 min through a triple mechanism, with a crosslinking efficiency increased by more than 80% compared with traditional methods and a yield of more than 99.5%. The application realizes chemical-photothermal dual-mode antibiosis through precise optimization of the ratio and reaction conditions and the function synergy of the components, with an inhibition rate of 96.86% and 97.23% for Escherichia coli and Staphylococcus aureus, which is increased by more than 62% compared with traditional silver-containing dressings; the hydrogel has a ROS clearance rate of 92.5% and an in-situ oxygen production rate increased by 58% compared with traditional methods, and can efficiently stop bleeding within 30 s, with a blood loss reduced by 90.3% compared with the blank group. The hydrogel has excellent biocompatibility and can comprehensively improve the pathological microenvironment of diabetic wounds, shortening the healing period of full-thickness skin wounds of diabetic rats from 21 days to 10 days, and providing a new and efficient biomedical material for the treatment of diabetic wounds.

This invention provides the application of transcription factor CUX1 in the preparation of products for the prevention and treatment of diabetic foot ulcers, belonging to the field of biomedical technology. Its key technical point lies in providing the application of transcription factor CUX1 as a target in the preparation of products for the prevention and treatment of diabetic foot ulcers. This application confirms the high expression of transcription factor CUX1 in diabetic foot ulcer wound tissue through specific verification experiments. Using a diabetic rat model of ischemic foot ulcers in the lower limbs, this invention is the first to clearly demonstrate a significant increase in the expression of transcription factor CUX1 in diabetic ulcer wound tissue. Using a high-glucose, high-lipid cell injury model, it is the first to demonstrate that CUX1 expression is significantly high after fibroblast injury due to high glucose and high lipid levels. It is the first to discover that transcription factors have a protective effect on fibroblasts injured by high glucose and high lipid levels. This invention provides a new approach for the treatment of diabetic foot ulcers and a new target for the development of diabetic wound healing.

The application discloses a new application of mulberry polysaccharide in preparation of a medicine for treating type 2 diabetes by regulating intestinal flora, and belongs to the technical field of medicinal and edible plant polysaccharides. In the application, a type 2 diabetes rat model is constructed by using high-sugar and high-fat feed in combination with streptozotocin, biochemical index detection, liver HE staining and oil red O staining, intestinal flora 16S rRNA high-throughput sequencing, and GC-MS detection of short-chain fatty acid content are carried out, so as to confirm that the mulberry polysaccharide can regulate the intestinal flora structure of T2DM rats, improve the secretion level of short-chain fatty acids, improve insulin resistance and glycolipid metabolism disorder, enhance the antioxidant capacity of the body, and repair the pathological damage of the liver. The application clearly defines the anti-type 2 diabetes mechanism of the mulberry polysaccharide, which takes the intestinal flora-short-chain fatty acid axis as the core. The mulberry polysaccharide is a natural low-toxicity medicinal and edible active ingredient, has no side effects of chemical hypoglycemic drugs, can be prepared into various oral medicine dosage forms, and is used for the prevention and clinical treatment of type 2 diabetes, so the application prospect is wide.

This invention relates to the field of biomedical technology, and particularly to a method and application for identifying active ingredients for the prevention and treatment of diabetes from non-medicinal Astragalus membranaceus slices. The method includes: first, qualitative and quantitative analysis of the chemical components of Astragalus membranaceus and longan slices; second, evaluation of its hypoglycemic efficacy using a diabetic rat model to verify the effects of Astragalus membranaceus and longan slices in lowering blood sugar, improving insulin resistance, and reducing inflammation; and finally, integration of non-targeted and pseudo-targeted metabolomics technologies to systematically identify the core active ingredients in key pathways for the prevention and treatment of diabetes by analyzing the correlation between chemical components and efficacy indicators. This invention not only reveals the main pharmacodynamic substances of Astragalus membranaceus in the prevention and treatment of diabetes, but also provides a theoretical basis and technical support for the development of related functional products or innovative drugs, and for comprehensively improving the utilization efficiency and economic value of Astragalus membranaceus resources.